China 98% 99% 99.9% Chemical Low Price Cannabidiol Cbd Powder CAS 13956-29-1 Cbd Oil, Find details about China Cannabidiol, Cbd Isolate Powder from 98% 99% 99.9% Chemical Low Price Cannabidiol Cbd Powder CAS 13956-29-1 Cbd Oil
CANNABIDIOL Chemical Properties |
Melting point | 62-63°C |
alpha | D27 -125° (0.066 g in 5 ml 95% ethanol); D18 -129° (c = 0.45 in ethanol) |
Boiling point | bp2 187-190° (bath temp 220°); bp0.001 130° |
density | d440 1.040 |
refractive index | nD20 1.5404 |
Fp | 11 °C |
storage temp. | 2-8°C |
InChIKey | QHMBSVQNZZTUGM-ZWKOTPCHSA-N |
CANNABIDIOL Usage And Synthesis |
Overview | Cannabidiol[CBD] is the main non-psychotropic component of the glandular. It displays a plethora of actions including anticonvulsive, sedative, hypnotic, antipsychotic, and anti-inflammatory and neuroprotective properties. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses[1, 2]. Cannabidiol was isolated in the late 1930s, but only in the 1963 were its structure and stereochemistry first elucidated[3]. Early studies focusing on CBD pharmacology started in the 1970s, with the first relevant finding concerning its hypnotic and anticonvulsant properties, published in 1981[4]. Since then, a large body of pharmacological effects has been demonstrated, both in preclinical and in clinical studies. Figure 1 the chemical structure of Cannabidiol; |
Indication | Being used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was applied for the following indications: 1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis[MS] who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy [7]; Sativex was also given a Notice of Compliance with Conditions(NOC/c) by Health Canada for the following indications: 1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis; 2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain[7]. |